Mariposa is developing an innovative solution to treat the rare skin condition epidermolysis bullosa simplex (EBS). The company is a spin out from Neem Biotech, based in Wales, which has a long history in pharmaceutical research and has extensive capabilities to develop commercially viable solutions for serious healthcare challenges.
About Mariposa
Developing a novel topical treatment for patients with epidermolysis bullosa (EBS)
The Science
Grounded on unique expertise in ajoene chemistry and its biological activities
Collaborate with us
Join in to innovate with us and to find a new treatment for EBS patients
Mariposa Therapeutics, a new private biotech company developing a novel topical treatment for patients with epidermolysis bullosa simplex (EBS) was established as a spin out from Neem Biotech, a company focused on the discovery of anti-virulence and anti-bacterial molecules utilising its...
